Amedica and Celling Biosciences will co-develop biologically-enhanced spinal fusion devices based on silicon nitride technology plus stem cell-based therapies.
Thus far, Celling Biosciences’ in vivo research indicates that mesenchymal stem cells may be optimized and proliferate when using silicon nitride vs. PEEK and titanium biomaterial. Studies suggest that the silicon nitride micro-environment promotes better cell adhesion and compatibility, with 5x greater cell adhesion vs. PEEK.
Following completion of initial research, Celling will translate early findings to clinical trials in spinal and orthopaedic applications.
Source: Amedica Corporation
Amedica and Celling Biosciences will co-develop biologically-enhanced spinal fusion devices based on silicon nitride technology plus stem cell-based therapies.
Thus far, Celling Biosciences' in vivo research indicates that mesenchymal stem cells may be optimized and proliferate when using silicon nitride vs. PEEK and titanium...
Amedica and Celling Biosciences will co-develop biologically-enhanced spinal fusion devices based on silicon nitride technology plus stem cell-based therapies.
Thus far, Celling Biosciences’ in vivo research indicates that mesenchymal stem cells may be optimized and proliferate when using silicon nitride vs. PEEK and titanium biomaterial. Studies suggest that the silicon nitride micro-environment promotes better cell adhesion and compatibility, with 5x greater cell adhesion vs. PEEK.
Following completion of initial research, Celling will translate early findings to clinical trials in spinal and orthopaedic applications.
Source: Amedica Corporation
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
